Today: 19 March 2026
Subscribe
Browse Category

NYSE:ABBV 28 November 2025 - 22 December 2025

AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie closed at $226.82 on Friday, Dec. 19, up 1.8%, with trading volume spiking to 18.6 million shares, well above average. The company remains in talks with the White House as U.S. drug pricing reforms accelerate, including “most-favored-nation” deals and new TrumpRx programs. AbbVie is expected to visit the White House after the holidays for further negotiations.
22 December 2025
···
AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

AbbVie shares closed at $226.82 on Friday, December 19, up 1.8% on heavy volume ahead of a holiday-shortened week. The company was not included in the White House’s December 19 list of drugmakers agreeing to new MFN pricing deals, leaving policy risk unresolved. Investors are watching for further announcements that could affect sentiment and trading.
21 December 2025
··
AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

AbbVie shares closed at $226.82 on Friday, up 1.8%, nearing a 52-week high with a market cap near $400 billion. U.S. drug pricing policy returned to focus after the Trump administration announced agreements with nine drugmakers, excluding AbbVie, which remains in upcoming negotiations. New Medicare pilot programs tied to international price referencing were also announced. Trading volume approached 19 million shares.
21 December 2025
··
AbbVie Stock (ABBV) News Today: Drug-Pricing Deal Watch, Skyrizi/Rinvoq Momentum, and Fresh Wall Street Forecasts (Dec. 20, 2025)

AbbVie Stock (ABBV) News Today: Drug-Pricing Deal Watch, Skyrizi/Rinvoq Momentum, and Fresh Wall Street Forecasts (Dec. 20, 2025)

AbbVie shares closed at $226.82 on Dec. 19, up 1.8%, with trading volume spiking after new U.S. drug-pricing policy announcements. Nine major drugmakers signed price-cut deals with the government, but AbbVie was not among them and remains under investor scrutiny. The stock outperformed pharma peers as investors repositioned amid policy uncertainty.
20 December 2025
·
AbbVie Stock (ABBV) After Hours on Dec. 19, 2025: What to Know Before the Next Market Open

AbbVie Stock (ABBV) After Hours on Dec. 19, 2025: What to Know Before the Next Market Open

AbbVie shares closed at $226.82, up 1.80% Friday, then slipped a penny in after-hours trading. Trading volume surged to about 17.4 million shares as investors reacted to White House drug-pricing deals. AbbVie was not among the nine drugmakers that agreed to new pricing terms and remains in talks with the administration, according to Reuters.
20 December 2025
··
AbbVie Stock (ABBV) After Hours Today: What’s Moving the Shares on Dec. 18, 2025 — and What to Watch Before the Market Opens Friday

AbbVie Stock (ABBV) After Hours Today: What’s Moving the Shares on Dec. 18, 2025 — and What to Watch Before the Market Opens Friday

AbbVie shares closed at $222.82, down 0.66% Thursday, then rose 0.31% to $223.51 after hours. Trading followed reports that AbbVie and other drugmakers may announce U.S. agreements Friday to lower certain drug prices under a White House initiative. No new AbbVie earnings were released. The S&P 500 gained 0.79% on the day.
19 December 2025
·
AbbVie Stock (ABBV) News, Forecasts and Analysis for Dec. 16, 2025: BofA Trims Target as Pipeline Catalysts Stay in Focus

AbbVie Stock (ABBV) News, Forecasts and Analysis for Dec. 16, 2025: BofA Trims Target as Pipeline Catalysts Stay in Focus

AbbVie shares fell 2.2% to $222.44 as of 17:54 UTC Tuesday after Bank of America cut its price target to $233 from $248 and kept a Neutral rating. The stock had traded near the top of its 52-week range before the drop. Analysts remain divided, with consensus 12-month targets ranging from $190 to $289. No major company-specific news drove the decline.
16 December 2025
··
AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025

AbbVie (ABBV) Stock: What to Know Before the US Market Opens on December 15, 2025

AbbVie shares closed at $223.32 Friday, down 0.3%, with a market cap near $395 billion. HSBC upgraded the stock to Buy with a $265 target, and Morgan Stanley lifted its target to $269, citing strong growth from Skyrizi and Rinvoq offsetting Humira declines. AbbVie raised 2025 adjusted EPS guidance to $10.61–$10.65 and announced a 5.5% dividend increase to $1.73 per share quarterly.
14 December 2025
··
AbbVie Stock (ABBV) Weekly Update & Week-Ahead Outlook: Analyst Upgrades, Pipeline Catalysts, and Key Levels — Updated Dec. 12, 2025

AbbVie Stock (ABBV) Weekly Update & Week-Ahead Outlook: Analyst Upgrades, Pipeline Catalysts, and Key Levels — Updated Dec. 12, 2025

AbbVie shares closed Friday at $223.32, down 0.29% as the S&P 500 fell. The stock was flat for the week, trading between $220.23 and $226.12. Volume spiked Wednesday after HSBC upgraded AbbVie to “Buy” and raised its price target to $265, while Morgan Stanley also boosted its target. AbbVie and OSE Immunotherapeutics amended their partnership on ABBV-230, with OSE regaining early-stage rights.
13 December 2025
AbbVie Stock (ABBV) After-Hours Update: What Happened on Dec. 12, 2025—and What to Watch Before the Next Market Open

AbbVie Stock (ABBV) After-Hours Update: What Happened on Dec. 12, 2025—and What to Watch Before the Next Market Open

AbbVie shares closed at $223.32 Friday, down 0.29%, and slipped further to $222.52 in after-hours trading. Morgan Stanley raised its price target on AbbVie to $269 from $261 while maintaining an Overweight rating. U.S. indexes fell broadly, with the S&P 500 down 1.07% and the Nasdaq off 1.69%. After-hours ABBV volume reached about 529,700 shares by 6:25 p.m. EST.
13 December 2025
·
AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie shares rebounded 2.98% to $236.28 on Nov. 21, 2025, with trading volume spiking to 7.9 million after three down days. Year-to-date, the stock is up about 22–26%, outpacing the S&P 500, but remains 7–9% below its October high. Forward P/E estimates range from 16x to 22x. Investors weigh strong Skyrizi and Rinvoq sales against Humira declines and regulatory risk.
11 December 2025
···
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie shares closed near $225 on December 1, 2025, valuing the company at about $400 billion. Q3 net revenue rose 9.1% to $15.78 billion, with adjusted EPS of $1.86 topping estimates. The company raised its 2025 profit forecast and approved a 5.5% dividend increase. Immunology sales climbed, while Humira revenue dropped below $1 billion.
1 December 2025
····
AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets

AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets

AbbVie closed November 30 at about $227, down 3% for the week but up over 30% in the past year. Shares slipped after news of steep Medicare price cuts for Linzess and Vraylar, while Canada approved public reimbursement for Skyrizi. AbbVie raised its 2026 dividend by 5.5%, with a forward yield just above 3%. Wall Street’s 12-month price target averages $240–$247.
30 November 2025
·
AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength

AbbVie Inc (ABBV) Stock on November 30, 2025: Analyst Downgrade, FDA Wins and Dividend Strength

AbbVie shares closed November at about $227, up 32% year to date but down 3% for the week amid Medicare pricing pressures. The stock’s trailing P/E remains above 170 due to one-off charges, while forward P/E is in the mid-teens. Wall Street Zen downgraded AbbVie from “Strong Buy” to “Buy” on November 30. The average analyst price target sits in the mid-$240s.
30 November 2025
·
AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie shares closed at $227.70 on November 28, near record highs after a 31.7% year-to-date gain. The company secured a major reimbursement win in Canada for Skyrizi in ulcerative colitis. Institutional investors reported changes in AbbVie holdings. Analysts questioned whether the stock remains undervalued after its recent rally.
29 November 2025
···
AbbVie Stock (ABBV) Today: Skyrizi’s Canada Win, Dividend Hike and Big-Money Moves — November 28, 2025

AbbVie Stock (ABBV) Today: Skyrizi’s Canada Win, Dividend Hike and Big-Money Moves — November 28, 2025

AbbVie closed Friday at $227.70, up 0.02% after a flat session. Canada’s drug agency recommended reimbursement for Skyrizi in ulcerative colitis, and AbbVie finalized a pricing deal with the national negotiator. Institutional investors adjusted positions, with some funds increasing and others reducing stakes. The stock’s year-to-date gain stands near 30–33%.
28 November 2025
·
1 2 3 4 5

Stock Market Today

  • Trinseo Misses Interest Payment, Secures Temporary Waivers from Lenders
    March 19, 2026, 5:57 PM EDT. Trinseo PLC missed an interest payment, triggering lender concerns. The company obtained temporary waivers from its financial stakeholders, allowing more time to evaluate options. Trinseo is currently in discussions to explore alternatives amid financial pressures. On March 2, 2026, the New York Stock Exchange announced plans to delist Trinseo's shares, intensifying challenges for the chemical firm. The situation underscores ongoing liquidity and credit risks faced by Trinseo as it navigates restructuring potential.
Go toTop